BMPS:MILBanca Monte dei Paschi di Siena S.p.A. Analysis
Data as of 2026-06-09 - not real-time
€10.10
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Banca Monte dei Paschi di Siena is trading at €10.10, matching its 52‑week high, and sits comfortably above its 20‑day SMA (9.04) and 50‑day SMA (8.74), confirming a bullish technical backdrop. The RSI of 72.9 indicates the stock is in overbought territory, while a bullish MACD histogram (+0.05) suggests momentum may still be intact. Valuation metrics are compelling: a trailing P/E of 7.3× is less than half the industry average of 16.9×, and the price‑to‑book of 1.08 is near book value. Dividend yield remains exceptionally high at 9.6% with a payout ratio of 62%, offering attractive cash returns despite a zero operating cash flow figure. Profitability is robust, with operating margins of 48% and net profit margins of 60%, and ROE of 13.3% supports earnings quality. However, the balance sheet shows €83.9 bn of debt against €52.0 bn of cash, and a 30‑day volatility of 47% signals price swings. The Fear‑Greed Index at 87.6 (Extreme Greed) reflects strong market sentiment, while analyst consensus is a “Buy” with a median target of €10.65.
The stock’s low beta (~0.52) suggests limited market‑wide risk, yet sector‑specific challenges—including Italian regulatory scrutiny and macro‑economic headwinds—remain. The high dividend yield may be hard to sustain given the lack of operating cash generation, and the recent Q1 profit increase (6.7% YoY) provides short‑term confidence but does not erase long‑term debt concerns. Overall, the blend of cheap valuation and strong earnings supports a positive outlook, but investors should monitor cash flow trends and potential pull‑backs from overbought conditions.
The stock’s low beta (~0.52) suggests limited market‑wide risk, yet sector‑specific challenges—including Italian regulatory scrutiny and macro‑economic headwinds—remain. The high dividend yield may be hard to sustain given the lack of operating cash generation, and the recent Q1 profit increase (6.7% YoY) provides short‑term confidence but does not erase long‑term debt concerns. Overall, the blend of cheap valuation and strong earnings supports a positive outlook, but investors should monitor cash flow trends and potential pull‑backs from overbought conditions.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI in overbought zone
- Price at resistance level
- Strong dividend yield
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued P/E relative to peers
- Robust profit margins
- Analyst target price above current level
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- High debt load versus cash reserves
- Potential regulatory headwinds in Italy
- Sustainable earnings growth despite cash flow concerns
Key Metrics & Analysis
Financial Health
Revenue Growth95.90%
Profit Margin59.63%
P/E Ratio7.3
ROE13.34%
ROA1.56%
P/B Ratio1.1
Industry P/E16.9
Technical Analysis
TrendBullish
RSI72.9
Support€8.44
Resistance€10.10
MA 20€9.04
MA 50€8.74
MA 200€8.25
MACDBullish
VolumeStable
Fear & Greed Index87.64
Valuation
Target Price€10.70
Upside/Downside5.90%
GradeUndervalued
TypeBlend
Dividend Yield9.61%
Risk Assessment
Beta0.52
Volatility47.11%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.